Lee H Harrison1, Kathleen A Shutt2, Kathryn E Arnold3, Eric J Stern4, Tracy Pondo5, Julia A Kiehlbauch6, Robert A Myers6, Rosemary A Hollick7, Susanna Schmink5, Marianne Vello3, David S Stephens8, Nancy E Messonnier5, Leonard W Mayer5, Thomas A Clark5. 1. Department of International Health, Johns Hopkins Bloomberg School of Public Health Infectious Diseases Epidemiology Research Unit, University of Pittsburgh, Pennsylvania. 2. Infectious Diseases Epidemiology Research Unit, University of Pittsburgh, Pennsylvania. 3. Georgia Emerging Infections Program Division of Public Health, Georgia Department Human of Resources. 4. National Center for Immunization and Respiratory Diseases Epidemic Intelligence Service Program, Centers for Disease Control and Prevention. 5. National Center for Immunization and Respiratory Diseases. 6. Maryland Department of Health and Mental Hygiene, Baltimore, Maryland. 7. Department of International Health, Johns Hopkins Bloomberg School of Public Health. 8. Georgia Emerging Infections Program Emory University School of Medicine VA Medical Center, Atlanta, Georgia.
Abstract
BACKGROUND: Meningococcal disease incidence in the United States is at an all-time low. In a previous study of Georgia high school students, meningococcal carriage prevalence was 7%. The purpose of this study was to measure the impact of a meningococcal conjugate vaccine on serogroup Y meningococcal carriage and to define the dynamics of carriage in high school students. METHODS: This was a prospective cohort study at 8 high schools, 4 each in Maryland and Georgia, during a school year. Students at participating schools received quadrivalent meningococcal conjugate vaccine that uses diphtheria toxoid as the protein carrier (MCV4-DT). In each state, 2 high schools were randomly assigned for MCV4-DT receipt by students at the beginning of the study, and 2 were randomly assigned for MCV4-DT receipt at the end. Oropharyngeal swab cultures for meningococcal carriage were performed 3 times during the school year. RESULTS: Among 3311 students, the prevalence of meningococcal carriage was 3.21%-4.01%. Phenotypically nongroupable strains accounted for 88% of carriage isolates. There were only 5 observed acquisitions of serogroup Y strains during the study; therefore, the impact of MCV4-DT on meningococcal carriage could not be determined. CONCLUSIONS: Meningococcal carriage rates in US high school students were lower than expected, and the vast majority of strains did not express capsule. These findings may help explain the historically low incidence of meningococcal disease in the United States.
BACKGROUND:Meningococcal disease incidence in the United States is at an all-time low. In a previous study of Georgia high school students, meningococcal carriage prevalence was 7%. The purpose of this study was to measure the impact of a meningococcal conjugate vaccine on serogroup Y meningococcal carriage and to define the dynamics of carriage in high school students. METHODS: This was a prospective cohort study at 8 high schools, 4 each in Maryland and Georgia, during a school year. Students at participating schools received quadrivalent meningococcal conjugate vaccine that uses diphtheria toxoid as the protein carrier (MCV4-DT). In each state, 2 high schools were randomly assigned for MCV4-DT receipt by students at the beginning of the study, and 2 were randomly assigned for MCV4-DT receipt at the end. Oropharyngeal swab cultures for meningococcal carriage were performed 3 times during the school year. RESULTS: Among 3311 students, the prevalence of meningococcal carriage was 3.21%-4.01%. Phenotypically nongroupable strains accounted for 88% of carriage isolates. There were only 5 observed acquisitions of serogroup Y strains during the study; therefore, the impact of MCV4-DT on meningococcal carriage could not be determined. CONCLUSIONS:Meningococcal carriage rates in US high school students were lower than expected, and the vast majority of strains did not express capsule. These findings may help explain the historically low incidence of meningococcal disease in the United States.
Authors: T Riordan; K Cartwright; N Andrews; J Stuart; A Burris; A Fox; R Borrow; T Douglas-Riley; J Gabb; A Miller Journal: Epidemiol Infect Date: 1998-12 Impact factor: 2.451
Authors: L H Harrison; M A Pass; A B Mendelsohn; M Egri; N E Rosenstein; A Bustamante; J Razeq; J C Roche Journal: JAMA Date: 2001-08-08 Impact factor: 56.272
Authors: Elizabeth A Mothershed; Claudio T Sacchi; Anne M Whitney; Gwen A Barnett; Gloria W Ajello; Susanna Schmink; Leonard W Mayer; Maureen Phelan; Thomas H Taylor; Scott A Bernhardt; Nancy E Rosenstein; Tanja Popovic Journal: J Clin Microbiol Date: 2004-01 Impact factor: 5.948
Authors: Scott E Kellerman; Katherine McCombs; Marsha Ray; Wendy Baughman; Michael W Reeves; Tanja Popovic; Nancy E Rosenstein; Monica M Farley; Paul Blake; David S Stephens Journal: J Infect Dis Date: 2002-06-07 Impact factor: 5.226
Authors: Lucy A McNamara; Jennifer Dolan Thomas; Jessica MacNeil; How Yi Chang; Michael Day; Emily Fisher; Stacey Martin; Tasha Poissant; Susanna E Schmink; Evelene Steward-Clark; Laurel T Jenkins; Xin Wang; Anna Acosta Journal: J Infect Dis Date: 2017-11-27 Impact factor: 5.226
Authors: Jay Lucidarme; Bingqing Zhu; Li Xu; Xilian Bai; Yuan Gao; Juan José González-López; Robert Mulhall; Kevin J Scott; Andrew Smith; Paola Stefanelli; Bianca Stenmark; Paul Torpiano; Georgina Tzanakaki; Ray Borrow; Zhujun Shao Journal: PLoS One Date: 2020-12-10 Impact factor: 3.240
Authors: Sandeep J Joseph; Nadav Topaz; How-Yi Chang; Melissa J Whaley; Jeni T Vuong; Alexander Chen; Fang Hu; Susanna E Schmink; Laurel T Jenkins; Lorraine D Rodriguez-Rivera; Jennifer D Thomas; Anna M Acosta; Lucy McNamara; Heidi M Soeters; Sarah Mbaeyi; Xin Wang Journal: mSphere Date: 2020-04-08 Impact factor: 4.389
Authors: Mustapha M Mustapha; Jane W Marsh; Kathleen A Shutt; Jessica Schlackman; Chinelo Ezeonwuka; Monica M Farley; David S Stephens; Xin Wang; Daria Van Tyne; Lee H Harrison Journal: J Infect Dis Date: 2021-06-15 Impact factor: 5.226